{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-110767","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.450724+00:00","generated_at":"2026-05-15T10:25:27.690528+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M","bullets":["FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.","Cash, cash equivalents $188.3M at year-end 2025; expected runway into 2028.","Q4 2025 net loss $8.3M vs $11.4M in Q4 2024; FY2025 net loss $42.8M.","R&D expenses Q4 $6.2M down from $9.3M; G&A $4.0M up from $2.9M.","Plan to initiate Phase 2b trial for refractory chronic cough in Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-110767","json":"https://secwatch.observer/filing/0001193125-26-110767.json","markdown":"https://secwatch.observer/filing/0001193125-26-110767.md","text":"https://secwatch.observer/filing/0001193125-26-110767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/0001193125-26-110767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/trvi-20260317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:25:27.690528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}